Search Results for: MET

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel CAV1 caveolin 1
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • Congenital generalized lipodystrophy (CGL)
Novel SH3KBP1 SH3 domain containing kinase binding protein 1
  • EGFR downregulation
  • Negative regulation of MET activity
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Reelin signalling pathway
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
Novel PABPC1 poly(A) binding protein cytoplasmic 1
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Deadenylation of mRNA
  • AUF1 (hnRNP D0) binds and destabilizes mRNA
  • Translation initiation complex formation
  • Regulation of expression of SLITs and ROBOs
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
Novel MRPL17 mitochondrial ribosomal protein L17
  • Mitochondrial translation initiation
  • Mitochondrial translation elongation
  • Mitochondrial translation elongation
  • Mitochondrial translation termination
Novel KLK2 kallikrein related peptidase 2
  • Activation of Matrix Metalloproteinases
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
Novel KCND2 potassium voltage-gated channel subfamily D member 2
  • Voltage gated Potassium channels
  • Phase 1 - inactivation of fast Na+ channels
  • Enflurane
  • Disopyramide
  • Imipramine
  • Promethazine
  • Miconazole
  • Dalfampridine
Novel SLC26A3 solute carrier family 26 member 3
  • Multifunctional anion exchangers
  • Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1)
Novel SLC26A4 solute carrier family 26 member 4
  • Multifunctional anion exchangers
  • Defective SLC26A4 causes Pendred syndrome (PDS)
  • Deafness, autosomal recessive
  • Thyroid dyshormonogenesis; Dyshormogenetic goiter
Novel FOXA3 forkhead box A3
  • Regulation of gene expression in beta cells
Novel CAMSAP3 calmodulin regulated spectrin associated protein family member 3
Novel RASSF7 Ras association domain family member 7
Novel SND1-IT1 SND1 intronic transcript 1
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • GP1b-IX-V activation signalling
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Isoprenaline
  • SF1126
  • Enzastaurin
  • Wortmannin
PTPN11 protein tyrosine phosphatase non-receptor type 11
  • Interleukin-6 signaling
  • PI3K Cascade
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • GPVI-mediated activation cascade
  • Prolactin receptor signaling
  • PIP3 activates AKT signaling
  • Spry regulation of FGF signaling
  • Signaling by SCF-KIT
  • GAB1 signalosome
  • Downstream signal transduction
  • PECAM1 interactions
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signaling by Leptin
  • Costimulation by the CD28 family
  • CTLA4 inhibitory signaling
  • PD-1 signaling
  • Signal regulatory protein family interactions
  • Netrin mediated repulsion signals
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Regulation of IFNG signaling
  • RET signaling
  • Interleukin-20 family signaling
  • MET activates PTPN11
  • Regulation of RUNX1 Expression and Activity
  • Interleukin-37 signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Interferon alpha/beta signaling
  • Regulation of IFNA signaling
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
  • FLT3 Signaling
  • STAT5 Activation
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Dodecyltrimethylammonium
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Metachondromatosis
LYN LYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Fc epsilon receptor (FCERI) signaling
  • Fc epsilon receptor (FCERI) signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated NF-kB activation
  • CD28 co-stimulation
  • CTLA4 inhibitory signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • CD22 mediated BCR regulation
  • Cyclin D associated events in G1
  • Platelet Adhesion to exposed collagen
  • Signaling by Erythropoietin
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Bosutinib
  • Ponatinib
  • Nintedanib
  • Fostamatinib
TP53 tumor protein p53
  • Activation of NOXA and translocation to mitochondria
  • Activation of PUMA and translocation to mitochondria
  • Pre-NOTCH Transcription and Translation
  • Oxidative Stress Induced Senescence
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • Oncogene Induced Senescence
  • DNA Damage/Telomere Stress Induced Senescence
  • SUMOylation of transcription factors
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Association of TriC/CCT with target proteins during biosynthesis
  • TP53 Regulates Metabolic Genes
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 Regulates Transcription of DNA Repair Genes
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Expression
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • G2/M DNA damage checkpoint
  • G2/M Checkpoints
  • Stabilization of p53
  • Transcriptional activation of cell cycle inhibitor p21
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • Transcriptional Regulation by VENTX
  • RUNX3 regulates CDKN1A transcription
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Factors involved in megakaryocyte development and platelet production
  • Acetylsalicylic acid
  • Zinc
  • Triethyl phosphate
  • AZD 3355
  • 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Osteosarcoma
  • Adrenal carcinoma
  • Thyroid cancer
  • Breast cancer
  • Basal cell carcinoma
  • Malignant melanoma
  • Pancreatic cancer
  • Gastric cancer
  • Malignant pleural mesothelioma
  • Non-small cell lung cancer
  • Esophageal cancer
  • Oral cancer
  • Multiple myeloma
  • Small cell lung cancer
  • Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
  • Glioma
  • Squamous cell carcinoma
  • Kaposi's sarcoma
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Cancer of the anal canal
  • Hepatocellular carcinoma
  • Choriocarcinoma
  • Vulvar cancer
  • Choroid plexus papilloma
  • Burkitt lymphoma
  • Adult T-cell leukemia
  • Hairy-cell leukemia
  • Bladder cancer
  • Chronic lymphocytic leukemia (CLL)
  • Penile cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Colorectal cancer
  • Laryngeal cancer
  • Chronic myeloid leukemia (CML)
PLCG1 phospholipase C gamma 1
  • ISG15 antiviral mechanism
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PLCG1 events in ERBB2 signaling
  • DAG and IP3 signaling
  • PLC-gamma1 signalling
  • Synthesis of IP3 and IP4 in the cytosol
  • Downstream signal transduction
  • Generation of second messenger molecules
  • Role of phospholipids in phagocytosis
  • Role of phospholipids in phagocytosis
  • PECAM1 interactions
  • EGFR interacts with phospholipase C-gamma
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Role of second messengers in netrin-1 signaling
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated cell proliferation
  • Constitutive Signaling by EGFRvIII
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Activated NTRK2 signals through PLCG1
  • Activated NTRK2 signals through PLCG1
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Activated NTRK3 signals through PLCG1
  • Activated NTRK3 signals through PLCG1
  • FCGR3A-mediated IL10 synthesis
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
SRC SRC proto-oncogene, non-receptor tyrosine kinase
  • Signaling by ERBB2
  • Nuclear signaling by ERBB4
  • Downregulation of ERBB4 signaling
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • Downstream signal transduction
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • G alpha (s) signalling events
  • G alpha (i) signalling events
  • G alpha (i) signalling events
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • RAF activation
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PTK2 signaling
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of RUNX1 Expression and Activity
  • RUNX2 regulates osteoblast differentiation
  • Regulation of RUNX3 expression and activity
  • Extra-nuclear estrogen signaling
  • Activated NTRK2 signals through FYN
  • Activated NTRK3 signals through PI3K
  • Activated NTRK3 signals through PI3K
  • Long-term potentiation
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric acid
  • Paratoulene phosphate
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • XL228
  • Tirbanibulin
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • PD-168393
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • PP-121
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
  • Nintedanib
  • Fostamatinib
PIK3R2 phosphoinositide-3-kinase regulatory subunit 2
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • Downstream signal transduction
  • Rho GTPase cycle
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Isoprenaline
  • SF1126

Page 1 out of 7 pages